中枢神经系统（CNS）肿瘤患者通常在其疾病过程中接受多模式治疗。这些干预措施的不良反应和并发症尚未得到系统研究，但在临床实践中具有重大挑战并影响功能和生活质量，特别是对于长期脑肿瘤幸存者的管理。欧洲神经肿瘤学协会（EANO）制定了建议，以防止、诊断和治疗成人原发性脑CNS肿瘤（淋巴瘤除外）患者人群出现不良反应和并发症，重点放在手术、放射治疗和药物治疗上。具体而言，我们还提供了关于药物治疗剂量调整、中断和再暴露的建议，这可作为临床试验中标准护理管理的参考。我们还总结了哪些干预措施是不必要的、无效的或禁忌的。本共识文件应作为标准治疗在临床试验内外的参考。© 作者 2023。由牛津大学出版社代表神经肿瘤学协会出版。版权所有。请发送电子邮件至journals.permissions@oup.com以获得授权。

Central nervous system (CNS) tumor patients commonly undergo multimodality treatment in the course of their disease. Adverse effects and complications from these interventions have not been systematically studied, but pose significant challenges in clinical practice and impact function and quality of life, especially in the management of long-term brain tumor survivors. Here the European Association of Neuro-Oncology (EANO) has developed recommendations to prevent, diagnose and manage adverse effects and complications in the adult primary brain CNS tumor (except lymphomas) patient population with a specific focus on surgery, radiotherapy and pharmacotherapy. Specifically, we also provide recommendations for dose adaptations, interruptions and re-exposure for pharmacotherapy that may serve as a reference for the management of standard of care in clinical trials. We also summarize which interventions are unnecessary, inactive or contraindicated. This consensus paper should serve as a reference for the conduct of standard therapy within and outside of clinical trials.© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.